Ixensor Co

Ixensor Co Operating Cash Flow

The Operating Cash Flow of Ixensor Co (6734.TWO) as of Oct 21, 2026 is -36.91 M TWD. In the previous year, Operating Cash Flow was -40.33 M TWD — a change of -8.49% (higher).

Operating Cash Flow

-36.91 MTWD

YoY

-8.49%

Last updated:

Operating Cash Flow of Ixensor Co is 2025 -36.91 M TWD. Operating Cash Flow of Ixensor Co was 2024 -40.33 M TWD. It decreases by -8.49% higher compared to the previous year.

The Ixensor Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-107.68 M TWD
Jan 1, 2019
-96.99 M TWD
Jan 1, 2020
-57.15 M TWD
Jan 1, 2021
-71.96 M TWD
Jan 1, 2022
8.12 M TWD
Jan 1, 2023
-46.20 M TWD
Jan 1, 2024
-40.33 M TWD
Jan 1, 2025
-36.91 M TWD
The Ixensor Co Operating Cash Flow history
YEAROperating Cash FlowYoY
-36.91 MTWD-8.49%
-40.33 MTWD-12.69%
-46.20 MTWD-669.07%
8.12 MTWD-111.28%
-71.96 MTWD+25.91%
-57.15 MTWD-41.08%
-96.99 MTWD-9.92%
-107.68 MTWD-2.65%
-110.61 MTWD+19.35%
-92.67 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ixensor Co Stock analysis

What does Ixensor Co do? iXensor Co., Ltd. generates revenue through its PixoTest Blood Glucose Monitoring System and ovulation detection system, targeting individuals managing diabetes and reproductive health. The company's technology platform measures biochemical parameters including blood sugar, luteinizing hormone, and cholesterol, providing data for diabetes management services. Its integrated medical device solutions serve customers seeking self-monitoring tools for chronic conditions and fertility tracking. The firm's products are designed for direct consumer use, with the PixoTest system offering blood glucose monitoring and the ovulation detection system supporting female hormone cycle management. These solutions leverage the company's platform to deliver personalized health insights without requiring third-party partnerships. The target segments include patients with diabetes and individuals tracking fertility cycles through biochemical monitoring. Ixensor Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ixensor Co stock

Operating Cash Flow of Ixensor Co is -36.91 M TWD in 2025.

Operating Cash Flow of Ixensor Co changed from -40.33 M TWD to -36.91 M TWD, representing a -8.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Ixensor Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Ixensor Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ixensor Co

All Key Metrics — Ixensor Co